Inventor · disambiguated record
Philip M. Roveto
Also filed as: ROVETO PHILIP · ROVETO PHILIP M · ROVETO PHILIP MARLEY
6 granted patents·6 pending applications·45 citations·filing 2010–2023
82Inventor score
Top patents by PatentIndex Score
12 records- 0189US8088794B2Substituted amide derivatives and methods of useKIM TAE-SEONG·Filed 2010·Granted Jan 3, 2012·14 cites·14 claims
- 0288US9593129B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2016·Granted Mar 14, 2017·5 cites·18 claims
- 0388US9296736B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Mar 29, 2016·7 cites·13 claims
- 0487US2024300892A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2023·Application pending·0 cites
- 0586US9376425B2Heterocyclic compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2012·Granted Jun 28, 2016·12 cites·37 claims
- 0683US8685983B2Method of treating cancer with substituted amide derivativesKIM TAE-SEONG·Filed 2011·Granted Apr 1, 2014·7 cites·5 claims
- 0780US2022169611A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2022·Application pending·0 cites
- 0874US2021179560A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2020·Application pending·0 cites
- 0967US2019062276A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2018·Application pending·0 cites
- 1065US2014011796A1Piperidinone derivatives as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2013·Application pending·0 cites
- 1146US2016002185A1Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Application pending·0 cites
- 1243US11407721B2CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2018·Granted Aug 9, 2022·0 cites·46 claims
Join the waitlist — get patent alerts
Get an alert when Philip M. Roveto files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →